Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Articles

Catch up on coverage from the second day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Day 2 Recap: AAD 2025

April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.

Late-Breaking Data: Super Responders With Delgocitinib for CHE

Late breaking data points to positive data for dupilumab for bullous pemphigoid.  

Late Breaking: Data From Pivotal Trial Reports Dupilumab Effective for Bullous Pemphigoid

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Adamson highlighted melanoma's rising incidence and the growing concerns of overdiagnosis at AAD 2025.

Adewole Adamson, MD, MPP: Addressing Melanoma Diagnosis and Overdiagnosis

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Bradley Burnam discusses results from an in-vivo model of atopic dermatitis.

Turn Therapeutics' Atopic Dermatitis Candidate Achieves 57% Reduction in Disease Severity in 7 Days

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

Adamson highlights key topics to expect at the AAD Annual Meeting, emphasizing the importance of tackling controversial issues and fostering collaboration.

Adewole Adamson, MD, MPP: Getting Ready to Tackle Dermatology's Key Challenges Issues at AAD 2025

Adewole (Ade) Adamson, MD, MPP, FAAD, assistant professor in the Department of Dermatology at Dell Medical School, University of Texas at Austin, is preparing for this week's 

2025 American Academy of Dermatology (AAD) Annual Meeting

, which will take place from March 7-11 in Orlando, Florida. 

At the meeting, Adamson will be participating in 2 sessions: "Approach to Melanoma Diagnosis" and "The 2025 Debates: Controversies in Dermatology," both of which will take place on Friday, March 7. These sessions promise to tackle pressing issues in dermatology, with an emphasis on melanoma diagnosis and the ongoing challenges in the specialty.

In previewing the event, Adamson shared key insights on the areas of focus for this year's meeting, specifically regarding the importance of tackling controversies within dermatology.

Adamson, who directs the Melanoma and Pigmented Lesion Clinic at Dell Seton Medical Center, works closely with patients at high risk for melanoma. He expressed that "areas of controversy are where we can learn the most and push the field the most." This perspective will drive his participation in discussions centered on advancing the field through rigorous dialogue. 

As he emphasized, the AAD provides a platform for "vigorous discussions around things that matter to us all and matter to our patients."

These discussions will cover key topics such as improving diagnostic techniques and treatment approaches for melanoma, particularly for high-risk patients. Adamson’s clinical focus on melanoma management, combined with his research into pigmented lesions, will be central to his contributions at the meeting.

"The AAD is a chance to engage with colleagues and really push forward our understanding of critical dermatologic issues," Adamson said. "By addressing areas of controversy, we can challenge ourselves and ultimately improve patient outcomes."

“A lot of the initiatives that we have within the medical affairs team are really focused on trying to understand what's important to the dermatology community: what's important to dermatologists, nurse practitioners, and physician assistants, and being able to work with them to advance that,” said Patrick Burnett, MD, PhD, in an interview with 

Burnett, a board-certified dermatologist and the chief medical officer of Arcutis Biotherapeutics, recently discussed new pipeline updates from Arcutis expected in 2025. In a previous interview, Burnett reviewed Arcutis’ new initiative with Odell Beckham Jr. to 

bring more awareness to seborrheic dermatitis

 and the positive impact of roflumilast foam (Zoryve) 0.3%.

Regarding updates from Arcutis in 2025, Burnett is looking forward to the continued expansion of roflumilast foam for scalp and body psoriasis, a pivotal readout of data for a topical JAK inhibitor for alopecia areata, the introduction of ARQ-234 for atopic dermatitis, and additional engagement with dermatology clinicians through medical education initiatives.

Patrick Burnett, MD, PhD, shares key updates expected in 2025 for therapeutics treating atopic dermatitis, alopecia areata, and more. 

Pipeline Updates on the Horizon From Arcutis Biotherapeutics 

A key focus of Arcutis’ plans in 2025 includes the continued expansion of roflumilast foam. While already FDA-approved for seborrheic dermatitis, Arcutis expects FDA approval in May 2025 for an additional indication—scalp and body psoriasis. The company has also submitted a lower-dose formulation (0.05%) for atopic dermatitis in children aged 2 to 5 years, with approval anticipated later in the year. Given the high prevalence of pediatric atopic dermatitis, this expansion could significantly impact treatment options.

Beyond roflumilast, Arcutis is advancing its broader dermatology pipeline. The company expects a pivotal readout in the first half of 2025 for its topical JAK inhibitor in alopecia areata. While JAK inhibitors have shown efficacy in treating alopecia, delivering them topically remains a challenge, according to Burnett. A successful topical formulation could offer an early-stage treatment alternative before systemic therapy is required. Additionally, Arcutis plans to submit an investigational new drug IND application for ARQ-234, a CD200R agonist in development as a biologic therapy for atopic dermatitis.

Arcutis is also engaging closely with the dermatology community through medical education initiatives. One such effort focuses on improving the management of seborrheic dermatitis in patients with tightly coiled hair, a subset often underrepresented in clinical discussions. The company is also exploring how the rise of nonsteroidal topical treatments—including roflumilast—is reshaping treatment algorithms, historically centered on systemic therapies and biologics.

Burnett emphasized the importance of connecting product development with real-world patient impact. He cited the company’s collaboration with Odell Beckham Jr. as an example of how roflumilast foam has directly benefited individuals, reinforcing Arcutis’ commitment to patient-centered innovation.

Odell Beckham Jr. and Arcutis tackle seborrheic dermatitis in a “Clear Win for Your Skin.” News release. Arcutis Biotherapeutics. February 4, 2025. Accessed March 3, 2025. 

https://www.arcutis.com/odell-beckham-jr-and-arcutis-tackle-seborrheic-dermatitis-in-a-clear-win-for-your-skin/

Arcutis Biotherapeutics is set to expand its dermatology pipeline in 2025, focusing on roflumilast foam for scalp and body psoriasis, and a lower-dose formulation for pediatric atopic dermatitis. The company anticipates a pivotal readout for a topical JAK inhibitor in alopecia areata, aiming to offer an early-stage treatment alternative. Additionally, Arcutis plans to submit an IND application for ARQ-234, a biologic therapy for atopic dermatitis. The company emphasizes patient-centered innovation, engaging with the dermatology community through medical education initiatives and collaborations.

Patrick Burnett, MD, PhD, shares key updates expected in 2025 for therapeutics treating atopic dermatitis, alopecia areata, and more.

Pipeline Updates on the Horizon From Arcutis Biotherapeutics

Prurigo Nodularis Burden of Disease

Video content above is prompted by the following:

How would you characterize the burden of disease, both physically and mentally, in patients with prurigo nodularis?

Prurigo nodularis imposes a significant burden on patients, both physically and mentally. The chronic, intense itching and skin lesions lead to substantial physical discomfort and can severely impact daily functioning. Patients often experience sleep disturbances and reduced quality of life due to persistent symptoms. Mentally, the condition can lead to psychological distress, including anxiety and depression, as patients struggle with the visible and often stigmatizing nature of the skin lesions. The chronic nature of the disease necessitates long-term management strategies, further contributing to the overall burden.

Melodie Young, MSN, A/GNP-C, discusses how prurigo nodularis imposes a significant physical and mental burden on patients, with chronic itching, skin lesions, and emotional distress leading to a reduced quality of life and increased anxiety and depression.

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Polls 

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

Cabtreo (Ortho Dermatologics; formerly known as IDP-126) was approved by the US Food and Drug Administration

 (FDA) in October 2023 for the treatment of patients aged 12 years and older with acne vulgaris. Cabtreo is the first FDA-approved fixed-dose triple-combination gel (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) for patients with acne. Cabtreo is expected to be available in Q1 of 2024.

, more than half (52.5%) of patients treated with Cabtreo achieved treatment success as measured by a 2-point or greater reduction from baseline in Evaluator’s Global Severity Score and clear or almost clear skin. In the first of the phase 3 trials, the proportion of patients treated with Cabtreo achieving clear or almost clear skin (49.6%) was significantly greater than patients being treated with a vehicle gel (24.9%). The second phase 3 trial demonstrated consistent significant rates of treatment success among Cabtreo- treated patients (50.5%) versus patients in the vehicle gel group (20.5%).

What are your thoughts about Cabtreo as the newest acne topical? Email us at 

Cabtreo, a fixed-dose triple-combination gel, received FDA approval in October 2023 for treating acne vulgaris in patients aged 12 and older. It combines clindamycin, adapalene, and benzoyl peroxide, marking the first such approved formulation. Clinical trials demonstrated its efficacy, with over half of the patients achieving significant improvement in acne severity. Phase 3 trials showed Cabtreo's superiority over a vehicle gel, with nearly 50% of patients achieving clear or almost clear skin. Cabtreo is anticipated to be available in the first quarter of 2024.

Click here to answer this week's acne poll.

Bradley Burnam

Articles

Latest Updated Articles